Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 4/20 | 0.37 |
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207735 | 1.00 | CYP1A2 (0.41) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL1461146 | 0.79 | NNMT (0.48) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL29850137 | 0.79 | POLB (0.50) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL31414709 | 0.79 | POLB (0.41) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL1460108 | 0.79 | POLB (0.50) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL20394372 | 0.79 | POLB (0.41) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL28847910 | 0.78 | CA1 (0.41) | POLBTDP1NNMTTXNRD1 | |
| SCHEMBL15542562 | 0.77 | POLB (0.36) | CYP1A2KMT2APOLBTDP1NQO2 | |
| SCHEMBL3227473 | 0.77 | NNMT (0.39) | CYP1A2KMT2APOLBTDP1NNMT | |
| SCHEMBL14975844 | 0.77 | CYP1A2 (0.39) | CYP1A2KMT2APOLBTDP1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20230056559-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| CN-115611925-A | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | PFIZER INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3919492-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | Medshine Discovery Inc. (CN) | 2021-12-08 | — | — | EP | disclosed |
| CN-108884093-B | Dopamine D3 ligand compound | 辉瑞公司 | 2021-07-09 | — | — | CN | disclosed |
| EP-3402796-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2019-02-14 | — | — | US | disclosed |
| EP-3402796-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | Pfizer Inc (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017122116-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017122116-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | CYP1A2 85/4885KMT2A 2302/4885POLB 2050/4885 |
| US-20230056559-A1 | PYRIMIDINYL GROUP-CONTAINING TRICYCLIC COMPOUND SERVING AS C-MET INHIBITOR | MET, MYC, METAP1 | CYP1A2 2537/4885KMT2A 945/4885POLB 3411/4885 |
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | DRD3, DRD2, DRD4 | CYP1A2 215/4885KMT2A 4021/4885POLB 3198/4885 |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | CYP1A2 359/4885KMT2A 549/4885POLB 3177/4885 |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | DRD3, DRD2, DRD4 | CYP1A2 215/4885KMT2A 4021/4885POLB 3198/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | CYP1A2 359/4885KMT2A 549/4885POLB 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.